Hims & Hers Health (NYSE:HIMS) Stock Price Expected to Rise, Leerink Partners Analyst Says

Hims & Hers Health (NYSE:HIMS) had its price target lifted by equities researchers at Leerink Partners from $17.50 to $25.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a “market perform” rating on the stock. Leerink Partners’ price objective would indicate a potential upside of 0.28% from the company’s current price.

A number of other analysts have also issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $25.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday, March 10th. Evercore set a $24.00 price objective on Hims & Hers Health in a research note on Tuesday, February 24th. TD Cowen cut their price objective on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating on the stock in a report on Tuesday, February 24th. Needham & Company LLC upgraded Hims & Hers Health from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a report on Monday, March 9th. Finally, BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $31.29.

Hims & Hers Health Trading Up 0.6%

NYSE HIMS traded up $0.16 during trading hours on Monday, reaching $24.93. The company had a trading volume of 31,297,281 shares, compared to its average volume of 35,503,699. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80. The stock has a market capitalization of $5.68 billion, a P/E ratio of 48.78, a price-to-earnings-growth ratio of 2.34 and a beta of 2.56. The stock has a 50-day moving average of $23.84 and a 200 day moving average of $37.34. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million during the quarter, compared to analysts’ expectations of $619.48 million. During the same period last year, the business earned $0.11 earnings per share. The business’s revenue for the quarter was up 28.4% on a year-over-year basis. As a group, research analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has initiated a stock repurchase plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Insider Activity

In other news, insider Deborah M. Autor sold 7,054 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $258,952.34. Following the completion of the transaction, the insider directly owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. The trade was a 53.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 23,090 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $35.72, for a total transaction of $824,774.80. Following the completion of the sale, the chief financial officer directly owned 94,333 shares in the company, valued at approximately $3,369,574.76. This trade represents a 19.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 80,463 shares of company stock worth $2,846,696 over the last three months. Company insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently modified their holdings of the company. Farallon Capital Management LLC raised its holdings in shares of Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. Invesco Ltd. grew its stake in shares of Hims & Hers Health by 502.2% during the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock worth $127,237,000 after purchasing an additional 2,128,587 shares in the last quarter. Norges Bank purchased a new position in Hims & Hers Health in the fourth quarter valued at $62,153,000. Clear Street LLC acquired a new stake in Hims & Hers Health in the second quarter valued at $83,582,000. Finally, Clear Street Group Inc. acquired a new stake in Hims & Hers Health in the third quarter valued at $87,372,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.